XOMA Corporation (XOMA)
| Market Cap | 409.14M |
| Revenue (ttm) | 2.23M |
| Net Income (ttm) | -12.71M |
| Shares Out | 11.02M |
| EPS (ttm) | -1.26 |
| PE Ratio | n/a |
| Forward PE | 714.29 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $37.10 |
| Previous Close | $36.20 |
| Change ($) | 0.90 |
| Change (%) | 2.49% |
| Day's Open | 36.77 |
| Day's Range | 36.13 - 38.01 |
| Day's Volume | 19,028 |
| 52-Week Range | 14.14 - 46.32 |
EMERYVILLE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor con...
XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty...
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:
EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered ...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 88...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of s...
XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda Pharmac...
EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (N...
As of late, it has definitely been a great time to be an investor in XOMA.
Xoma (XOMA) delivered earnings and revenue surprises of 52.38% and -75.78%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering...
EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technol...
EMERYVILLE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 d...
EMERYVILLE, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned $1.9 million in payments from two partners. The Co...
EMERYVILLE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:
As of late, it has definitely been a great time to be an investor in XOMA.
Xoma (XOMA) delivered earnings and revenue surprises of 13.16% and -74.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts Partners continue to advance clinical assets within the ...
Live video feed will be available on XOMA’s website Live video feed will be available on XOMA’s website
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, In...
EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the ...
XOMA (XOMA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in XOMA.
Raises $22 million from existing stockholders Raises $22 million from existing stockholders
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Why you should keep an eye on these potential outperformers this month.
EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candid...
EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to r...
EMERYVILLE, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its intent to commence a rights offering pursuant to which th...
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Includes royalty interest in NIR178 Includes royalty interest in NIR178
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cant...
EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s busin...
Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After years of decline, spending on offshore oil projects is on track to bounce back in 2019.
About XOMA
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for... [Read more...]
| Industry Biotechnology | |
| CEO James R. Neal | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol XOMA |
Financial Performance
In 2019, XOMA's revenue was $18.37 million, an increase of 246.67% compared to the previous year's $5.30 million. Losses were -$1.98 million, -85.15% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is 46.00, which is an increase of 23.99% from the latest price.